doi: 10.1007/s10620-012-2216-2 20 BrownL
References: Sun Y, Veccia D, Liu BDX, Tse W, Fass R, Song G
281 As approved by the FDA in 2018 for the treatment of ATTR-PN, Inotersen requires regular safety monitoring for potential adverse events, particularly thrombocytopenia and glomerulonephritis
synthesized two amphiphilic molecules mPEG-TK-DA and DTPA-N10-10 with ROS-scavenging functions, and self-assembled AGL through hydrophobic and hydrophilic interactions, forming multi-site ROS-scavenging nanoparticles called PDN@AGL
Finally, it is important to note that the original cost measures were not used during database entry, which may have introduced errors